Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth (Status and Outlook) 2025-2031

September 2025 | 112 pages | ID: GF065E750639EN
LP Information

Abstracts

According to this study, the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size will reach US$ million by 2031.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.

United States market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) players cover Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Forecast” looks at past sales and reviews total world Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales in 2024, providing a comprehensive analysis by region and market sector of projected Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales for 2025 through 2031. With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) industry.

This Insight Report provides a comprehensive analysis of the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Corticosteroid Therapy
• IVIG Treatment
• Plasma Exchange Therapy
• Immunosuppressive Drug Therapy
• Immunomodulator Therapy
• Other

Segmentation by Application:

• Hospital
• Specialist Neurology Clinic
• Research and Academic Laboratories

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Teijin Pharma
• Shire
• Pfizer
• Octapharma
• Momenta Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Kedrion
• Grifols
• CSL Behring (CSL Limited)
• Bio Products Laboratory
• Baxter
• MedDay Pharmaceuticals
• GeNeuro Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)
  2.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Country/Region (2020, 2024 & 2031)
2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Type
  2.2.1 Corticosteroid Therapy
  2.2.2 IVIG Treatment
  2.2.3 Plasma Exchange Therapy
  2.2.4 Immunosuppressive Drug Therapy
  2.2.5 Immunomodulator Therapy
  2.2.6 Other
2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type
  2.3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
2.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Application
  2.4.1 Hospital
  2.4.2 Specialist Neurology Clinic
  2.4.3 Research and Academic Laboratories
2.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application
  2.5.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)

3 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SIZE BY PLAYER

3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Player
  3.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Player (2020-2025)
  3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Player (2020-2025)
3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) BY REGION

4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025)
4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth (2020-2025)
4.4 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth (2020-2025)
4.5 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth (2020-2025)
4.6 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)
5.2 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025)
5.3 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025)
6.2 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025)
6.3 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)
7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025)
7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Region (2020-2025)
8.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025)
8.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET FORECAST

10.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Region (2026-2031)
  10.1.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Region (2026-2031)
  10.1.2 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.1.3 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.1.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.1.5 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
10.2 Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Country (2026-2031)
  10.2.1 United States Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.2.2 Canada Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.2.3 Mexico Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.2.4 Brazil Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
10.3 APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Region (2026-2031)
  10.3.1 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast
  10.3.2 Japan Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.3.3 Korea Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.3.4 Southeast Asia Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.3.5 India Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.3.6 Australia Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
10.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Country (2026-2031)
  10.4.1 Germany Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.4.2 France Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.4.3 UK Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.4.4 Italy Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.4.5 Russia Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
10.5 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Region (2026-2031)
  10.5.1 Egypt Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.5.2 South Africa Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.5.3 Israel Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
  10.5.4 Turkey Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast
10.6 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Type (2026-2031)
10.7 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecast

11 KEY PLAYERS ANALYSIS

11.1 Teijin Pharma
  11.1.1 Teijin Pharma Company Information
  11.1.2 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Teijin Pharma Main Business Overview
  11.1.5 Teijin Pharma Latest Developments
11.2 Shire
  11.2.1 Shire Company Information
  11.2.2 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Shire Main Business Overview
  11.2.5 Shire Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments
11.4 Octapharma
  11.4.1 Octapharma Company Information
  11.4.2 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Octapharma Main Business Overview
  11.4.5 Octapharma Latest Developments
11.5 Momenta Pharmaceuticals
  11.5.1 Momenta Pharmaceuticals Company Information
  11.5.2 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Momenta Pharmaceuticals Main Business Overview
  11.5.5 Momenta Pharmaceuticals Latest Developments
11.6 Mitsubishi Tanabe Pharma Corporation
  11.6.1 Mitsubishi Tanabe Pharma Corporation Company Information
  11.6.2 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Mitsubishi Tanabe Pharma Corporation Main Business Overview
  11.6.5 Mitsubishi Tanabe Pharma Corporation Latest Developments
11.7 Kedrion
  11.7.1 Kedrion Company Information
  11.7.2 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Kedrion Main Business Overview
  11.7.5 Kedrion Latest Developments
11.8 Grifols
  11.8.1 Grifols Company Information
  11.8.2 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Grifols Main Business Overview
  11.8.5 Grifols Latest Developments
11.9 CSL Behring (CSL Limited)
  11.9.1 CSL Behring (CSL Limited) Company Information
  11.9.2 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 CSL Behring (CSL Limited) Main Business Overview
  11.9.5 CSL Behring (CSL Limited) Latest Developments
11.10 Bio Products Laboratory
  11.10.1 Bio Products Laboratory Company Information
  11.10.2 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Bio Products Laboratory Main Business Overview
  11.10.5 Bio Products Laboratory Latest Developments
11.11 Baxter
  11.11.1 Baxter Company Information
  11.11.2 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.11.4 Baxter Main Business Overview
  11.11.5 Baxter Latest Developments
11.12 MedDay Pharmaceuticals
  11.12.1 MedDay Pharmaceuticals Company Information
  11.12.2 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.12.4 MedDay Pharmaceuticals Main Business Overview
  11.12.5 MedDay Pharmaceuticals Latest Developments
11.13 GeNeuro Pharmaceuticals
  11.13.1 GeNeuro Pharmaceuticals Company Information
  11.13.2 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
  11.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, Gross Margin and Market Share (2020-2025)
  11.13.4 GeNeuro Pharmaceuticals Main Business Overview
  11.13.5 GeNeuro Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Corticosteroid Therapy
Table 4. Major Players of IVIG Treatment
Table 5. Major Players of Plasma Exchange Therapy
Table 6. Major Players of Immunosuppressive Drug Therapy
Table 7. Major Players of Immunomodulator Therapy
Table 8. Major Players of Other
Table 9. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & ($ millions)
Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
Table 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & ($ millions)
Table 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)
Table 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Player (2020-2025) & ($ millions)
Table 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Player (2020-2025)
Table 17. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Products Offered
Table 18. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025) & ($ millions)
Table 22. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Region (2020-2025)
Table 23. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Country/Region (2020-2025) & ($ millions)
Table 24. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Country/Region (2020-2025)
Table 25. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & ($ millions)
Table 26. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Country (2020-2025)
Table 27. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & ($ millions)
Table 28. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
Table 29. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & ($ millions)
Table 30. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)
Table 31. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025) & ($ millions)
Table 32. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Region (2020-2025)
Table 33. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & ($ millions)
Table 34. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & ($ millions)
Table 35. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & ($ millions)
Table 36. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Country (2020-2025)
Table 37. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & ($ millions)
Table 38. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & ($ millions)
Table 39. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025) & ($ millions)
Table 40. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & ($ millions)
Table 41. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Table 43. Key Market Challenges & Risks of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Table 44. Key Industry Trends of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Table 45. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Region (2026-2031) & ($ millions)
Table 46. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share Forecast by Region (2026-2031)
Table 47. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Type (2026-2031) & ($ millions)
Table 48. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Forecast by Application (2026-2031) & ($ millions)
Table 49. Teijin Pharma Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 50. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 51. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 52. Teijin Pharma Main Business
Table 53. Teijin Pharma Latest Developments
Table 54. Shire Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 55. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 56. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 57. Shire Main Business
Table 58. Shire Latest Developments
Table 59. Pfizer Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 60. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 61. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 62. Pfizer Main Business
Table 63. Pfizer Latest Developments
Table 64. Octapharma Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 65. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 66. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 67. Octapharma Main Business
Table 68. Octapharma Latest Developments
Table 69. Momenta Pharmaceuticals Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 70. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 71. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 72. Momenta Pharmaceuticals Main Business
Table 73. Momenta Pharmaceuticals Latest Developments
Table 74. Mitsubishi Tanabe Pharma Corporation Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 75. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 76. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 77. Mitsubishi Tanabe Pharma Corporation Main Business
Table 78. Mitsubishi Tanabe Pharma Corporation Latest Developments
Table 79. Kedrion Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 80. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 81. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 82. Kedrion Main Business
Table 83. Kedrion Latest Developments
Table 84. Grifols Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 85. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 86. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 87. Grifols Main Business
Table 88. Grifols Latest Developments
Table 89. CSL Behring (CSL Limited) Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 90. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 91. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 92. CSL Behring (CSL Limited) Main Business
Table 93. CSL Behring (CSL Limited) Latest Developments
Table 94. Bio Products Laboratory Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 95. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 96. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 97. Bio Products Laboratory Main Business
Table 98. Bio Products Laboratory Latest Developments
Table 99. Baxter Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 100. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 101. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 102. Baxter Main Business
Table 103. Baxter Latest Developments
Table 104. MedDay Pharmaceuticals Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 105. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 106. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 107. MedDay Pharmaceuticals Main Business
Table 108. MedDay Pharmaceuticals Latest Developments
Table 109. GeNeuro Pharmaceuticals Details, Company Type, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Area Served and Its Competitors
Table 110. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offered
Table 111. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 112. GeNeuro Pharmaceuticals Main Business
Table 113. GeNeuro Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Country/Region (2024)
Figure 8. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type in 2024
Figure 10. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hospital
Figure 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Hospital (2020-2025) & ($ millions)
Figure 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Specialist Neurology Clinic
Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Specialist Neurology Clinic (2020-2025) & ($ millions)
Figure 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Research and Academic Laboratories
Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Research and Academic Laboratories (2020-2025) & ($ millions)
Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application in 2024
Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Player in 2024
Figure 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Region (2020-2025)
Figure 19. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2020-2025 ($ millions)
Figure 20. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2020-2025 ($ millions)
Figure 21. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2020-2025 ($ millions)
Figure 23. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Value Market Share by Country in 2024
Figure 24. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Region in 2024
Figure 29. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
Figure 30. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)
Figure 31. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 35. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Country in 2024
Figure 38. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
Figure 39. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)
Figure 40. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 41. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 54. APAC Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 55. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 57. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 58. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 59. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 60. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 61. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 62. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 63. Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 65. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 66. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 67. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 68. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 69. UK Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 70. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 71. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 72. Egypt Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 73. South Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 74. Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 75. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)
Figure 76. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size 2026-2031 ($ millions)